Physician profile
Timothy D Blake
NPI 1891790986
$4,710.19
in general payments reported to CMS, 2019-2025
29 companies · $580 in 2025
The $580 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $256 · 2021: $522 · 2022: $712 · 2023: $1,094 · 2024: $923 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,596.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,169.03 | 2019-2025 | Clareon, Rocklatan, Simbrinza |
| Bausch & Lomb Americas INC. | $587.97 | 2022-2025 | Xiidra, Infuse, Miebo |
| Abbvie INC. | $337.12 | 2022-2025 | Ozurdex, Alphagan P, Vuity |
| Aerie Pharmaceuticals, INC. | $314.44 | 2019-2021 | |
| Oyster Point Pharma, INC. | $292.49 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Amgen INC. | $267.97 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $246.80 | 2022-2023 | Tepezza |
| Ivantis, INC | $228.60 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $220.49 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $159.15 | 2024-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $150.78 | 2019-2024 | Cequa |
| Novartis Pharmaceuticals Corporation | $106.06 | 2019-2022 | |
| Sight Sciences, INC. | $88.61 | 2019-2024 | Omni Surgical System |
| Optovue, INC. | $63.42 | 2019 | |
| Astellas Pharma US INC | $54.02 | 2024-2025 | Izervay |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $46.05 | 2020-2021 | |
| Johnson & Johnson Vision Care, INC. | $44.23 | 2019-2020 | |
| Omeros Corporation | $42.82 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $41.94 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $39.65 | 2022-2023 | Rayone Spheric, Omidria, Rayone Aspheric |
| Allergan, INC. | $39.32 | 2020-2021 | |
| Dompe US, INC. | $35.36 | 2025 | Oxervate |
| Glaukos Corporation | $24.90 | 2024 | Idose |
| Biotissue Holdings INC. | $24.77 | 2019 | |
| Eyepoint US, INC. | $18.79 | 2019 | |
| Apellis Pharmaceuticals, INC. | $17.50 | 2025 | Syfovre |
| Ocular Therapeutix, INC. | $17.20 | 2023 | Dextenza |
| Vyera Pharmaceuticals, LLC | $16.22 | 2020 | |
| Shire North American Group INC | $14.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Blake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.